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Heat-shock proteins (Hsps) are molecular chaperones that are ubiquitously expressed but are also induced in cells exposed to
stressful stimuli. Hsps have been implicated in the induction and propagation of several diseases. This paper focuses on regulatory
factors that control the transcription of the genes encoding Hsps. We also highlight how distinct transcription factors are able
to interact and modulate Hsps in diﬀerent pathological states. Thus, a better understanding of the complex signaling pathways
regulating Hsp expression may lead to novel therapeutic targets.
1.Introduction
The heat-shock proteins (Hsps) are a group of highly
conserved proteins with major physiological roles in pro-
tein homeostasis [1, 2]. In most cell types even prior to
stress Hsps constitute 1%-2% of total protein, suggesting
an important role for these proteins in the biology and
physiology of the unstressed cell. These particularly concern
regulating the folding and unfolding of other proteins.
The proteins are named, however, because they were ﬁrst
identiﬁed on the basis of their increased synthesis following
exposure to elevated temperatures [3]. Subsequently it has
been clearly shown that they can be induced following a
variety of stressful stimuli. Some Hsps, such as Hsp90 (each
Hsp is named according to its mass in kilodaltons) are
detectable at signiﬁcant levels in unstressed cells, increasing
in abundance following a suitable stimulus, whilst others
such as Hsp70 exist in both constitutively expressed and
inducible forms that is activated by stressful stimuli [4, 5].
The dual role of Hsps in both normal and stressed
cells, evidently requires the existence of complex regulatory
processes which ensure that the correct expression pat-
tern is produced. Indeed, such processes must be opera-
tive at the very earliest stages of embryonic development
since the genes encoding Hsp70 and Hsp90 have been
shown to be amongst the ﬁrst embryonic genes which are
transcribed [6, 7].
The induction of Hsps in response to various stresses is
dependent on the activation of speciﬁc members of a family
of transcription factors, the heat-shock factors (HSFs) which
bind to the heat-shock element (HSE) in the promoters of
the genes encoding Hsps [8]. Four HSFs (HSF1 to −4) have
been cloned from a number of organisms and their roles
have now been characterised. Only HSF1 and HSF3 have
been shown to be involved in regulating Hsps in response to
thermal stress whereas HSF2 and HSF4 are involved in Hsp
regulation in unstressed cells and their levels are regulated
in response to a wide variety of biological processes such
as immune activation and cellular diﬀerentiation [8]. In
general, however, the stimuli which induce such alterations
in Hsp gene expression under nonstress conditions are
poorly characterized and the mechanisms by which they act
areunclear.Inthispaper,wediscussrecentstudiesindicating
that Hsps are not only regulated by HSFs alone, but also by
transcription factors which are able to interact or cooperate
with HSF1 and modulate the transcriptional regulation of
Hsps in response to nonstressful stimuli. More recently, as
will be explained later, it has also been reported that HSF2,2 Biochemistry Research International
like HSF1 can also play a role as a stress-inducible factor in
promoting the induction of Hsps under certain conditions.
2.TranscriptionalRegulation of Hspsby
the HSFFamily
2.1. HSF1. As mentioned previously, HSF1 has been iden-
tiﬁed as the HSF that mediates stress-induced Hsp gene
expression in response to environmental stressors. Such
stresses cause HSF1 oligomerization and nuclear translo-
calization, followed by enhanced DNA binding on the Hsp
gene promoters. Recent studies have shown that HSF1 is
negatively regulated by Hsp70 and Hsp90, therefore suggest-
ing a negative-feedback loop for the regulation of Hsp70
and Hsp90 genes following a heat-shock response [8–10].
HSF1 is known to undergo posttranslational modiﬁcation
by various processes including phosphorylation, acetylation,
and sumoylation [8]. Both phosphorylation and sumoyla-
tion are involved in regulating the transactivation capacity
of HSF1 [8]. More recent, whereas p300 has been shown
to acetylate HSF1, deacetylation by the NAD+-dependent
sirtuin (SIRT1) is involved in the attenuation phase of the
heat-shock response by preventing HSF1 acetylation and
DNA binding [8].
The kinases responsible for phosphorylating HSF1
on several serine sites include glycogen synthase kinase
3β(GSKβ) and c-jun N-terminal kinase (JNK) [11, 12]. The
cytokine interleukin 6 (IL-6) has been shown to derepress
HSF1 by reducing the activity of GSKβ [13]. However, a
positive role of HSF1 phosphorylation in the stress-induced
activation of Hsp gene expression is also known to occur.
The exact mechanism of this eﬀect has not been fully
elucidated, although the protein kinase CK2 seems to be
involved in enhancing transcriptional activity and the DNA
binding of HSF1 by phosphorylating the threonine 142
residue [14]. It is suggested that activation may also involve
dephosphorylation of HSF1 [11].
The key role of HSF1 has been supported by the ﬁndings
that cells lacking this crucial factor exhibited defects in Hsp
induction following exposure to heat shock [15]. Moreover,
cells lacking HSF1 were susceptible to apoptotic cell death
following exposure to heat stress [15]. In addition, mice
lacking HSF1 also had elevated levels of tumour necrosis
factor α (TNF-α), which resulted in increased mortality after
endotoxin and inﬂammatory challenge [15]. Interestingly,
HSF1 has been shown to also modulate other genes such
as interleukin-1β and c-fos [16, 17], suggesting a role for
HSF1 in regulating stress responsive genes other than those
encoding Hsps.
More recently, it has been reported that HSF1 also
functions in the circadian clock as a circadian transcription
factor. The circadian clock enables an organism to adapt to
conditions by presetting the area in the brain that controls
behavioural changes. Circadian transcription factors are
known to be regulated in a timely and rhythmic fashion
Thus, using a novel technique of diﬀerential display of DNA-
binding proteins (DDDPs), HSF1 was shown to be highly
rhythmic in its transcriptional activity. Moreover, HSF1
enhanced the expression of Hsps at the onset of the dark
phase, when the animals start to be behaviourally active.
Furthermore,Hsf1-deﬁcientmicehavealongerfree-running
period and therefore more active than wild-type littermates,
suggesting a combined role for HSF1 in the mammalian
timekeeping and cytoprotection systems [18].
2.2. HSF2. As mentioned earlier, Hsp gene expression is cru-
cial not only for the survival of cells exposed to extracellular
stress stimuli, but also during normal cellular processes such
asembryonicdevelopmentandcellulardiﬀerentiation.HSF2
has now been described as the factor involved in regulating
Hsps under nonstressful conditions. For example, it was
previously reported that Hsp70 expression is activated when
K562 cells are induced by hemin and this process requires
activation of HSF2 [19]. HSF2 exists as two isoforms,
HSF2α and HSF2β, due to alternative splicing, where the
HSF2α isoform is predominantly expressed in adult tissue,
while the HSF2β isoform is predominantly expressed in
embryonic tissue [20]. HSF2 DNA binding activity is high
during early embryogenesis in tissues such as the heart,
central nervous system, and testis [20]. The importance of
HSF2 in development was recently reported and Hsf2-null
mice display gametogenesis defects and brain abnormalities
characterized by enlarged ventricles [21].
During mitosis, the genome is well known to be
compacted in order for chromosomes to be segregated
during cytokinesis. However, some gene promoters such
as the inducible Hsp70i (heat stress-induced upregulation)
remain uncompacted. The factors that control and prevent
this process of compaction or bookmarking have been
recently characterized. For example, Hsp70i bookmarking
is now known to be mediated by HSF2, which binds this
promoter in mitotic cells, recruits protein phosphatase 2A,
and interacts with the CAP-G subunit of the condensin
enzyme to promote eﬃcient dephosphorylation and inac-
tivation of condensin complexes in the vicinity, thereby
preventing compaction at this site [22]. Blocking HSF2-
mediated bookmarking by HSF2 RNA interference decreases
hsp70i induction and survival of stressed cells in the G1
phase,whichdemonstratesthebiologicalimportanceofgene
bookmarking. HSF2 has also been shown to be bound to the
HSEpromoterelementsofotherheat-shockgenes,including
Hsp90 and Hsp27, as well as the proto-oncogene c-fos [23].
These data suggest that HSF2 is important for constitutive as
well as stress-inducible expression of HSE-containing genes.
It is also known that HSF2 can form heterotrimers with
HSF1. Following certain stress, HSF1 is activated and HSF1-
HSF2 heterotrimers are formed. Heat-shock stress dimin-
ishes the levels of HSF2 and restricts heterotrimerization
by limiting the availability of HSF2. It has been suggested
that HSF1-HSF2 heterotrimerization provides a switch that
integrates the transcriptional activation in response to
speciﬁc stimuli during developmental processes; for review
see [8].
2.3. HSF3. HSF3 was originally identiﬁed in avian cells and
no reports have yet described HSF3 in other organisms. LikeBiochemistry Research International 3
HSF1, HSF3 is also heat-stress responsive [24]. However, the
threshold temperature required to activate HSF3 and HSF1
are diﬀerent in that HSF1 is activated by less severe heat
shock than HSF3 [24]. Previously, HSF3 was reported to
bind to c-Myb, a transcription factor involved in cellular
proliferation and required for the G1/S transition of the
cell cycle, which also paralleled the expression of Hsp70
[25]. These studies suggest that HSF3/cMyb interaction may
be involved in cell cycle-dependent expression of Hsps.
Furthermore, more recently, it has been shown that HSF3/c-
Myb association is disrupted by direct binding of the p53
tumour suppressor transcription factor to HSF3, resulting in
inhibition of Hsp70 expression [26].
2.4.HSF4. IncontrasttoHSF1andHSF2proteins,whichare
expressed in most tissues, the level of HSF4 protein is very
low in many mammalian tissues except in lung and brain
[27]. There are at least two isoforms, HSF4a and HSF4b,
which are derived by alternative RNA-splicing events. HSF4b
is able to activate transcription whereas HSF4a does not and
this diﬀerential eﬀect has not yet been characterized [27, 28].
Interestingly, mutations of HSF4 have been associated with
dominant inherited cataracts in human [29]. More recently,
HSF4 has been revealed to have a role in regulating lens-
speciﬁc gamma-crystalline genes during lens development
[30].
3. The Role of Non-HSFTranscription
Factors in Modulating Hsp Gene Expression
by theSTATandNF-IL6Pathways
The phenotype of mice lacking HSF1 is normal in the
absence of stress and expression of Hsp70 and Hsp90 in
cells lacking HSF1 is similar to wild-type cells, although
they exhibit a defect in the heat-shock response following
heat stress [13]. These studies suggest that other HSFs
may compensate for the lack of HSF1 and/or that other
transcription factors may also be responsible for expression
of Hsps under normal growth conditions. Recent studies
from our laboratory have identiﬁed a separate group of
transcription factors that are activated by distinct cytokines
and are able to modulate Hsp70 and Hsp90 gene expression.
These factors include STAT1, STAT3, and NF-IL6 and their
functional roles are described below.
The STATs are a family of cytoplasmic transcription fac-
tors that mediate intracellular signalling initiated at cytokine
cell surface receptors and transmitted to the nucleus. STATs
are activated by phosphorylation on conserved tyrosine and
serine residues on their C-terminal domains by the Janus
kinases (JAKs) and MAP kinase families, respectively. This
allows the STATs to dimerise and translocate to the nucleus
and thereby regulate gene expression [31]. Interferon-γ is
a potent activator of STAT1, whilst the interleukin-6 (IL-6)
family members including IL-6, leukaemia inhibitory factor
(LIF), and CT-1 primarily activate STAT3 [31].
Our laboratory has previously shown that STAT1 and
STAT3 have opposing actions on apoptotic cell death in
various cell types [32]. We reported that overexpression of
STAT1 is able to enhance apoptotic cell death in cardiac
myocytes exposed to ischaemia reperfusion (I/R) injury
whereas overexpression of STAT3 with STAT1 is able to
reduce the levels of STAT1-induced cell death following I/R
by modulating the expression of pro- and antiapoptotic
genes [33]. Furthermore, these eﬀects on apoptosis require
serine-727 but not tyrosine-701 phosphorylation on the C-
terminal transactivation domain of STAT1 [34, 35].
Moreover, we have shown that STAT1 is able to modulate
the activity of p53 and its eﬀects on apoptosis [36]. These
eﬀects involve STAT1/p53 protein-protein interaction with
STAT1 acting as a coactivator for p53 [36]. We have also
demonstratedthatSTAT1isalsoabletointeractwithanother
p53 family member p73 [37]. However, in contrast to
STAT1-p53 interaction which enhances p53 transcriptional
activity, the STAT1-p73 interaction was shown to reduce
p73 functional activity on similar p53-responsive genes [37].
Thus, STAT1 is able to have diﬀerential eﬀects on p53/p73
transcriptional activity.
A link between p53 activity and the HSF1-heat-shock
response pathway has recently been documented by the
ﬁnding that HSF1 interacts with stress-responsive activator
of p300 (Strap) transcription cofactor, a key factor con-
trolling the DNA damage response through its ability to
regulate p53 activity [38]. Moreover, Strap augments HSF1
binding and chromatin acetylation in Hsp genes, most
probably through the p300 histone acetyltransferase activity
of p300 itself. Furthermore, cells depleted of Strap do not
surviveunderheat-shockconditions[38].Overall,thesedata
indicate that Strap is an essential cofactor that acts at the
level of chromatin control to regulate heat-shock-responsive
transcription.
The cytokine IL-6 is known to stimulate two distinct
signalling pathways, resulting in the activation of two
diﬀerent classes of cellular transcription factors [39]. Thus,
initial studies showed that a variety of IL-6-inducible genes
contained binding sites for a transcription factor named
NF-IL6 (nuclear factor IL-6), which showed high homology
with the rat-liver nuclear factor C/EBP (CCAAT-enhancer-
binding protein), and is therefore also known as C/EBPβ
[40]. Subsequently, another member of the C/EBP family,
known as NF-ILβ or C/EBPδ, was identiﬁed and shown to
form heterodimers with NF-IL6, resulting in a synergistic
transcriptional eﬀect [41]. After exposure of cells to IL-6,
NF-IL6 is phosphorylated, resulting in its enhanced ability to
stimulate transcription [41] whereas NF-IL6β is synthesized
de novo [41]. As mentioned above the second pathway which
is stimulated by IL-6 is the JAK/STAT3 signalling pathway.
It is generally accepted that the NF-IL6/NF-IL6β and
STAT3-signalling pathwaysallow IL-6to activatetwodistinct
sets of genes, each of which is responsive to one of these
pathways. Thus, class 1 acute-phase proteins (such as α1-acid
glycoprotein, haptoglobin, C-reactive protein, and serum
amyloid) contain response elements for NF-IL6 and NF-
IL6β and these factors have been shown to be involved in
the activation of these genes following IL-6 treatment [32].
In agreement with this idea, these genes are stimulated by
exposure of cells to IL-1 which also stimulates NF-IL6/NF-
IL6β activity without aﬀecting STAT3 [42]. In contrast,4 Biochemistry Research International
type 2 acute-phase genes such as ﬁbrinogen, thiostatin,
and α2 microglobulin are not inducible by IL-1 and lack
binding sites for NF-IL6/NF-IL6β. Instead, these genes
contain binding sites allowing binding of STAT3, which
is responsible for activation of these genes in response to
IL-6 [42].
4.Role of STAT1,STAT3, andNF-IL6 Factorsin
ModulatingHsps
We previously reported [43] that IL-6 can induce increased
expression of the 90 kDa heat-shock protein (hsp90) in a
variety of diﬀerent cell types. The hsp90β gene promoter was
shown to be responsive to IL-6 and could also be activated
by NF-IL6 or NF-IL6β [43]. Moreover, a short region of the
promotercontaininganNF-IL6-bindingsitewasessentialfor
activation of the promoter by both IL-6 and NF-IL6. This
promoter region could confer responsiveness both to IL-6
andtooverexpressionofNF-IL6onaheterologouspromoter.
These ﬁndings suggested that hsp90 was a member of the
class of IL-6-responsive genes that were activated by NF-
IL6/NF-IL6β.
Interestingly, this short region of the promoter also
contains binding sites for STAT3 and the hsp90 promoter
can be activated also by this factor. Moreover, overexpression
of NF-IL6 and STAT3 has a synergistic eﬀect on the hsp90
promoter and both these signalling pathways appear to be
required for activation of the hsp90 promoter by IL-6 [44].
Despite their synergistic action in IL-6 signalling, however,
these two pathways have opposite eﬀects on the heat-shock-
mediated regulation of the hsp90 promoter. Thus STAT3
reduces the stimulatory eﬀect of heat shock whereas NF-
IL6 enhances it. When applied together, heat shock and
IL-6 produce only weak activation of the hsp90 promoter
compared with either stimulus alone, indicating that the
inhibitory eﬀect of STAT3 on HSF predominates under these
conditions [44]. In contrast, IL-1, which activates only the
NF-IL6 pathway, synergizes with heat shock to produce
strong activation of hsp90 [44]. These results therefore open
up a new aspect of hsp90-gene regulation which is additional
to and interacts with the heat-shock-activated pathway.
Previously, we had also examined whether STAT1 is
able to modulate Hsp expression. We showed that IFN-γ
treatment increases the levels of Hsp-70 and Hsp-90 and also
enhances the activity of the Hsp-70 and Hsp-90β promoters
withtheseeﬀectsbeingdependentonactivationoftheSTAT1
transcription factor by IFN-γ [45]. These eﬀects were not
seen in a STAT1-deﬁcient cell line, indicating that IFN-γ
modulates Hsp induction via a STAT1-dependent pathway.
The eﬀect of IFN-γ/STAT1 was mediated via the same short
regionoftheHsp-70/Hsp-90promoters,whichalsomediates
the eﬀects of NF-IL6 and STAT3 and can bind STAT1 [45].
This region also contains a binding site for the stress-
activated transcription factor HSF1. We showed that STAT1
and HSF1 interact with one another via a protein-protein
interaction and produce a strong activation of transcription
[45]. This is in contrast to the previous ﬁnding that STAT3
andHSF1antagonizeoneanotherandweshowedthatSTAT3
andHSF1donotinteractdirectly.Toourknowledge,thiswas
the ﬁrst report of HSF1 interacting directly via a protein-
protein interaction with another transcription factor. Such
protein-protein interactions and the binding of a number of
diﬀerent stress and cytokine-activated transcription factors
to a short region of the Hsp-90 and Hsp-70 gene promoters
are likely to play a very important role in Hsp gene activation
bynonstressfulstimuliandtheintegrationoftheseresponses
with the stress response of these genes. Moreover, our
ﬁndings that STAT1 can interact with p53 and that both
these factors are able to modulate the eﬀects of HSF1 on Hsp
expression, suggests diﬀerent interacting partners of HSF1
may aﬀect HSF1-mediated transcriptional regulation.
5.LinkingHSF1,STAT1,STAT3,andNF-IL6
Elevationto Pathological Diseases
A number of disease states have been shown to exhibit
elevated levels of Hsps [46]. This includes patients with
systemic lupus erythematosus (SLE) who have elevated levels
of Hsp90. Interestingly, elevated levels of circulating IL-
6 have also been reported in SLE [47], and the levels
have been shown to be correlated with disease activity,
being highest in patients with active disease. Moreover,
spontaneous production of IgG by normal and SLE-derived
B lymphocytes in culture can be enhanced by the addition of
exogenousIL-6andinhibitedbyantibodytoIL-6[48].These
ﬁndings therefore suggest that IL-6 might play a role in the
pathogenesis of autoimmune diseases. Moreover, infusion
of an antibody to IL-6 can relieve disease symptoms in
lupus-proneNZB/NZWF1mice[49].Furthermore,elevated
levels of Hsp90 in SLE correlated with levels of IL-6 and of
autoantibodies to Hsp90 [50].
In order therefore to test directly the role of IL-6 in
regulating Hsp90 expression in vivo we have used mice
which have been artiﬁcially engineered to express elevated
levels of IL-6 either by being made transgenic for extra
copies of the IL-6 gene [51] or by inactivation of the
gene encoding the transcription factor C/EBPβ which also
results in the elevation of IL-6 levels in these mice [52]. In
these experiments, elevated levels of Hsp90 were observed
in both the IL-6 transgenic and the C/EBPβ knock-out
mice [53]. Hence, the elevated IL-6 levels induced in these
animals are indeed paralleled by increased levels of Hsp90
compared to normal control mice. In addition, it was also
observed that in both IL-6 transgenic and C/EBPβ knock-
out animals, elevated hsp90 was associated with the speciﬁc
production of autoantibodies to Hsp90. It is also of interest
that inactivation of the IL-6 gene in the C/EBPβ knock-out
mice resulted in the suppression of Castleman-like disease
normally observed in these animals and a reduction in the
production of autoantibodies.
These results support a model in which elevated levels of
IL-6 in SLE patients induce increased levels of Hsp90 protein
which in turn results in the production of autoantibodies to
this protein. Additionally, IL-10 is also elevated in SLE and
IL-10 was demonstrated to enhance Hsp90 gene expression
[54]. Therefore, these studies strongly suggest that IL-6 andBiochemistry Research International 5
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Figure 1: Signal transduction pathways activated by STAT1, STAT3, NF-IL6, p53, and the heat-shock response (HSR) via HSF1 binding
to the heat-shock response element (HSE) and integrating to modulate Hsp transcription, which is known to be dysregulation in diﬀerent
pathological diseases.
IL-10 are likely to play a critical role in the regulation of
Hsp90 levels and autoantibody production in autoimmune
disease states.
As described above, NF-IL6 performs diverse functions,
participating in the regulation of genes that contribute to the
knownacutephaseresponse,butalsotoglucosemetabolism,
and tissue diﬀerentiation, including adipogenesis and
hematopoiesis [55–57]. Hsps and STAT3 have also been
found at increased levels in many solid tumours and haema-
tological malignancies [58, 59]. Their expression may in part
account for the ability of malignant cells to maintain protein
homoeostasis even in the hostile hypoxic microenvironment
of the tumour. Thus, STAT3 seems to function as an anti-
apoptotic factor,especiallyinnumerousmalignancies,where
STAT3 is often constitutively active/phosphorylated and
STAT3activationhasbeenassociatedwithadvancedstagesof
metastaticcancerssuchasprostatecancer[60].Furthermore,
STAT3 behaves as an oncogene, and is able to transform
normal ﬁbroblast cells which can then form tumours in
nude mice [61]. Thus, targeting STAT3 activation has been
suggested to be an attractive anticancer therapy [60].
Likewise, Hsps allow tumour cell survival, growth,
and metastasis, even in growth factor-deprived conditions,
by allowing continued protein translation and cellular
proliferation [62, 63]. Therefore, targeting of Hsps with
chemical inhibitors may be beneﬁcial in multiple oncogenic
processes. [64]. Further evidence for a link between Hsps
and cancer was reported from studies in the HSF1 knockout
mice, which showed reduced development of tumours, and
HSF1 deﬁciency rendered cultured cells highly refractory
to transformation initiated by mutated RAS or by platelet-
derived growth factor-B (PDGF-B) overexpression [65, 66].
Similarly, HSF1 depletion decreased viability of multiple
human cancer cell lines, but had no eﬀect on normal cells,
suggesting that HSF1 provides critical relief to the cellular
stresses experienced by cancer cells [67]. It is therefore
plausible that the STAT3-Hsp interactions may be one such
survival pathway that allows tumour cell survival, growth
and metastasis in cancers.
6. Conclusion
This review paper demonstrates the modulation of Hsps by
a group of transcription factors other than the traditional
HSF family under normal nonstressful conditions and also
in several disease states. The ﬁnding that the responses to
these factors occur around the HSF DNA binding site in the
Hsp gene promoters, suggests that HSF1 as well as other
HSFs are able to interact or cooperate with STATs or NF-
IL6familymembers.Furtherstudiestoidentifynovelprotein
interacting partners for HSFs will also provide insight into
the regulation of Hsps and other molecular chaperones.
Unravelling the mechanistic basis of this cooperation will
undoubtedly enhance our understanding of the interdepen-
dentrelationshipbetweendistinctHSFsandtheirinteraction
with other factors in the complex regulatory processes which
ensure that the correct Hsp expression pattern is produced
under diﬀerent physiological states (Figure 1).
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